Soleno Therapeutics Stock Investor Sentiment

SLNO Stock  USD 52.71  3.13  5.61%   
About 66% of Soleno Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Soleno Therapeutics suggests that many traders are alarmed. Soleno Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Soleno Therapeutics. Many technical investors use Soleno Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

Soleno Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Soleno Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
a day ago at investing.com         
Baird maintains Outperform on Soleno, keeps 72 target
Investing News at Macroaxis
3 days ago at gurufocus.com         
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Gurufocus Stories at Macroaxis
few days ago at seekingalpha.com         
Soleno slides after FDA review extension of its Prader-Willi syndrome treatment
seekingalpha News
few days ago at gurufocus.com         
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR ...
Gurufocus Stories at Macroaxis
few days ago at gurufocus.com         
Soleno Tumbles 17 percent as FDA Extends Review Timeline for Prader-Willi Treatment
Gurufocus Stories at Macroaxis
few days ago at finance.yahoo.com         
Soleno Tumbles 17 percent as FDA Extends Review Timeline for Prader-Willi Treatment
Yahoo News
few days ago at benzinga.com         
What the Options Market Tells Us About Soleno Therapeutics
benzinga news
few days ago at investors.com         
Soleno Therapeutics Clears Key Benchmark, Hitting 90-Plus RS Rating
Investors Business Daily at Macroaxis
over a week ago at news.google.com         
Soleno Therapeutics Reports Q3 Progress and Financials - TipRanks
Google News at Macroaxis
over a week ago at news.google.com         
PERCEPTIVE ADVISORS LLC Reduces Stake in Soleno Therapeutics Inc - GuruFocus.com
Google News at Macroaxis
over two weeks ago at gurufocus.com         
Perceptive Advisors LLC Increases Stake in Soleno Therapeutics Inc
Gurufocus Stories at Macroaxis
over two weeks ago at gurufocus.com         
Avoro Capital Advisors LLC Increases Stake in Soleno Therapeutics Inc
Gurufocus Stories at Macroaxis
over two weeks ago at investing.com         
Soleno Therapeutics SWOT analysis rare disease stock poised for FDA decision
Investing News at Macroaxis
over two weeks ago at news.google.com         
Heres Why Were Not At All Concerned With Soleno Therapeutics Cash Burn Situation - Yahoo Finance
Google News at Macroaxis
over two weeks ago at simplywall.st         
Companies Like Soleno Therapeutics Can Afford To Invest In Growth
Simply Wall St News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Soleno Therapeutics that are available to investors today. That information is available publicly through Soleno media outlets and privately through word of mouth or via Soleno internal channels. However, regardless of the origin, that massive amount of Soleno data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Soleno Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Soleno Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Soleno Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Soleno Therapeutics alpha.

Soleno Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 7 shares by Yen Kristen of Soleno Therapeutics at 48.3 subject to Rule 16b-3
09/10/2024
2
Disposition of 888 shares by Patricia Hirano of Soleno Therapeutics at 41.6671 subject to Rule 16b-3
09/20/2024
3
Disposition of 1359 shares by Patricia Hirano of Soleno Therapeutics at 36.4853 subject to Rule 16b-3
09/25/2024
4
Stocks With Rising Relative Price Strength Soleno Therapeutics
09/26/2024
5
Soleno Therapeutics Clears Technical Benchmark, Hitting 90-Plus RS Rating
10/09/2024
6
Soleno Therapeutics Pioneering Treatment for Prader-Willi Syndrome with DCCR
10/16/2024
7
Acquisition by Anish Bhatnagar of 100000 shares of Soleno Therapeutics at 36.7 subject to Rule 16b-3
10/18/2024
8
Soleno Therapeutics to Participate in Upcoming November Investor Conferences
10/28/2024
9
Soleno Therapeutics GAAP EPS of -1.83 misses by 1.22
11/07/2024
10
Heres Why Were Not At All Concerned With Soleno Therapeutics Cash Burn Situation - Yahoo Finance
11/12/2024
11
Perceptive Advisors LLC Increases Stake in Soleno Therapeutics Inc
11/15/2024
12
Soleno Therapeutics Clears Key Benchmark, Hitting 90-Plus RS Rating
11/25/2024
13
Soleno Tumbles 17 percent as FDA Extends Review Timeline for Prader-Willi Treatment
11/26/2024
14
Baird maintains Outperform on Soleno, keeps 72 target
11/29/2024
When determining whether Soleno Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soleno Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soleno Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soleno Therapeutics Stock:
Check out Soleno Therapeutics Hype Analysis, Soleno Therapeutics Correlation and Soleno Therapeutics Performance.
To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.79)
Return On Assets
(0.48)
Return On Equity
(0.91)
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.